This HTML5 document contains 230 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://dx.doi.org/10.1038/
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q27851478
rdf:type
wikibase:Item
schema:description
наукова стаття, опублікована в березні 2010 vitenskapelig artikkel articol științific tieteellinen artikkeli 2010年論文 artigo científico (publicado na 2010) επιστημονικό άρθρο мақолаи илмӣ article scientific scienca artikolo teaduslik artikkel artigo científico (publicado na 2010-03) 2010年论文 bài báo khoa học 2010年論文 artículu científicu espublizáu en 2010 scientific article vedecký článok (publikovaný 2010-03) บทความทางวิทยาศาสตร์ мақолаи илмӣ სამეცნიერო სტატია 2010年论文 научная статья 2010年论文 2010 թուականի Մարտին հրատարակուած գիտական յօդուած wetenschappelijk artikel (gepubliceerd in 2010-03) 2010年論文 научни чланак مقالهٔ علمی article científic vědecký článek publikovaný v roce 2010 2010年论文 articolo scientifico (pubblicato il 2010-03) artikull shkencor 2010 nî lūn-bûn videnskabelig artikel (udgivet 2010-03) سائنسی مضمون 2010년 논문 mokslinis straipsnis artigo científico vetenskaplig artikel wissenschaftlicher Artikel 2010年论文 научни чланак 2010年論文 artículo científico publicado en 2010 bilimsel makale 2010 թվականի մարտին հրատարակված գիտական հոդված vitskapeleg artikkel article scientifique (publié 2010) artykuł naukowy ২০১০-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ מאמר מדעי 2010年论文 научна статия naučni članak artikulong pang-agham 2010年の論文 2010年論文 tudományos cikk مقالة علمية (نشرت في مارس 2010)
p:P577
wds:Q27851478-5B1452F2-6106-46FF-B3DB-BB6705BBF105
wdt:P577
2009-08-03T00:00:00Z
p:P407
wds:Q27851478-75D31845-18E8-4B14-9E16-A8781B524861
wdt:P407
wd:Q1860
p:P2860
wds:Q27851478-18833C35-CF96-40EC-99AC-A5D0111952AD wds:Q27851478-1911AD20-0739-4FD4-9472-7F3D8AD601AC wds:Q27851478-1BD48796-7B83-4A8E-B220-70FC9572089F wds:Q27851478-2F6C136D-76C0-467F-835F-AA1884511A36 wds:Q27851478-31182230-CC12-4F77-8779-8248117C862C wds:Q27851478-31D6DEB8-97A7-4A49-897A-4010297B8EC9 wds:Q27851478-32F7DEB6-C57D-458B-B673-30EC19A43688 wds:Q27851478-039D8FD4-E86F-4E6B-9045-E294B13E863F wds:Q27851478-05C0C303-4FC5-4DEE-AF11-7370A105ED19 wds:Q27851478-0873120E-77F1-4BDA-8DC8-B96C88D5538D wds:Q27851478-088E7A2F-C038-490B-B468-927822118B2B wds:Q27851478-0A064316-8F9D-49B7-9656-4D4EB01D4D4E wds:Q27851478-8116FF08-420B-4B7D-B3AC-EFA5C12CC650 wds:Q27851478-8979CC15-1E72-452D-9697-1787416DEC89 wds:Q27851478-8B4F808C-DB0A-419C-A444-B90E83EC32B4 wds:Q27851478-A6FA6708-7132-49EF-A96C-9228CFAA832F wds:Q27851478-A77C084F-7018-4F94-8BFF-AD0B5ED86AB1 wds:Q27851478-A959A0A8-9802-4BD9-B3E1-B18D396DFFF5 wds:Q27851478-473E7F48-2460-456E-B729-6F0EB57FE5A6 wds:Q27851478-474A8207-AE59-40DE-A7C6-9E35C45BCFD4 wds:Q27851478-4F90B104-DFDF-4470-B1D6-8C253FFD4F2F wds:Q27851478-56E86158-4469-49D6-8651-F95026BD17BC wds:Q27851478-572307A9-10FF-42E8-9112-8D36B9DE1AAF wds:Q27851478-6AAB4DA8-8A75-4A20-807D-ECD1EC23EE3B wds:Q27851478-6AD2DE81-B98C-4AD6-9AB5-8965629341B8 wds:Q27851478-6B115E5C-D9C4-4457-AD38-2AC1B0B981F6 wds:Q27851478-6FCB676F-3B05-411D-BD5B-B73C8AEA6248 wds:Q27851478-7781707A-E28B-4A20-94F5-67F11B3B992E wds:Q27851478-E8F84179-4D0E-4CB3-8D54-2F192999A1F1 wds:Q27851478-FA6F02A7-5155-4DB4-A22D-5B2ABBA5E2C7 wds:Q27851478-FB48AD65-1210-4E7F-A907-EA2352FB228C wds:Q27851478-FF01D7AF-9E69-428D-9B5E-C2CBCC55EB8E wds:Q27851478-B39B87A6-1A6C-4099-BBD5-5546CB463D6A wds:Q27851478-BF049092-D1B4-44D7-9BE8-97DCFB1C6BA4 wds:Q27851478-C49EA468-7179-49DC-AFBC-122B0410E25C wds:Q27851478-C6C3104F-DAA9-419F-9118-7CF018A012E0 wds:Q27851478-D5C9FAA2-1EDA-4477-8604-7175EE8BB90E wds:Q27851478-D83C53B3-D746-49B9-BE7A-41FAEB5FD300 wds:Q27851478-DAC68B64-E726-4316-B86A-713D419EF805
wdt:P2860
wd:Q35644819 wd:Q34288599 wd:Q55474881 wd:Q33368469 wd:Q54485612 wd:Q33497931 wd:Q43412047 wd:Q77613965 wd:Q44985080 wd:Q71123629 wd:Q27860585 wd:Q35992308 wd:Q36895601 wd:Q71403076 wd:Q41192947 wd:Q45272426 wd:Q44908719 wd:Q33503007 wd:Q40468548 wd:Q43679624 wd:Q31983627 wd:Q47620252 wd:Q54061091 wd:Q31960456 wd:Q80796096 wd:Q40433265 wd:Q33148445 wd:Q33331938 wd:Q46963348 wd:Q41559705 wd:Q57103839 wd:Q45096277 wd:Q41307831 wd:Q44879936 wd:Q54219747 wd:Q33503973 wd:Q71572036 wd:Q67718907 wd:Q34192665
p:P2093
wds:Q27851478-BD06B3BE-8757-4851-B60B-6A9E09D64B9D wds:Q27851478-BD332EA9-A5AB-42FD-9146-13137423D4C1 wds:Q27851478-D4F26FE9-144B-4DD2-801F-C3E8823E3912 wds:Q27851478-E6DD47C9-8435-407A-8C4D-8BF65301E3A4 wds:Q27851478-41A795D6-6EB6-4169-8388-00D47F1EC855 wds:Q27851478-5D02C5F7-DE93-4B20-802B-BE5B5D13C325 wds:Q27851478-8440A76E-15C1-4CD0-9BA9-E60E9E378057 wds:Q27851478-7CF23F77-ACA4-4B46-8F43-A9ACC167604E wds:Q27851478-98C177E7-FB4B-4FE8-889A-79A6C36F67A4 wds:Q27851478-1AB5EFC2-E11E-4FEE-9B27-26C0E7A82CC3 wds:Q27851478-40315D0D-B6DB-4FEE-8C2B-6A07731F0DFE wds:Q27851478-2EC9535B-C4DB-4341-9FAB-4D8FE28397D6
wdt:P2093
P P Peethambaram B A Barrette J M Reid S M Ansell D A Gastineau D J Inwards L F Porrata H J Long M A Elliott G L Keeney I N M Micallef M M Ames
rdfs:label
Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.
skos:prefLabel
Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.
schema:name
Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.
p:P50
wds:Q27851478-9DBB4EC0-E930-4148-8BAF-4CE573E24EA3 wds:Q27851478-8763D727-7325-49B7-A0DA-D9F5B8C020EC wds:Q27851478-CCC4C51F-1518-48B2-A94D-634BBD77D41F wds:Q27851478-C390403E-9EBC-442E-86C3-8837C498989E wds:Q27851478-B6F14DA2-32DB-48B5-A97A-D33630750E61 wds:Q27851478-E7F58F54-8FEC-4570-AD15-F38D541940F1 wds:Q27851478-0A8A3FE5-078E-4E04-BC9D-8D8250EA8B60 wds:Q27851478-3F908643-75E7-490C-9B6A-6EC12823E2AB wds:Q27851478-2BDE84D9-872C-4944-A77B-A955513B439F wds:Q27851478-0FBA3C3D-1987-42B1-8045-56AB8EE25A6D
wdt:P50
wd:Q112850014 wd:Q112869593 wd:Q112869610 wd:Q96186734 wd:Q57052163 wd:Q37838558 wd:Q87294607 wd:Q66419394 wd:Q92977647 wd:Q40592168
p:P1476
wds:Q27851478-84F69E9E-057F-44F8-AC67-1C75A7800470
wdt:P1476
Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma
p:P304
wds:Q27851478-5AEA0844-2E0B-494C-B2E7-76E80AA4B50C
wdt:P304
490-497
p:P31
wds:Q27851478-1D82CB43-ABB2-4DA4-A9A9-42FCA67AD6D4
wdt:P31
wd:Q13442814
p:P921
wds:Q27851478-FD36E02F-4F0D-4815-9715-8E5F961A14CE wds:Q27851478-CA8F2D9E-EA8F-4B15-8FFD-6E81DC96A61E wds:Q27851478-95569AE1-1CD0-4F1E-B46A-2E0215B47CC5
wdt:P921
wd:Q5452194 wd:Q415588 wd:Q15730500
p:P698
wds:Q27851478-4827BB70-1D89-4046-93CB-213231560790
wdtn:P698
n12:19648970
wdt:P698
19648970
p:P1433
wds:Q27851478-8E1CBE17-3888-4E59-93E3-1018CE1BF66A
wdt:P1433
wd:Q4941523
p:P433
wds:Q27851478-30633D38-6215-4D64-A2F4-23A8C8801DBA
p:P478
wds:Q27851478-BEF4A95E-4811-4B5B-BA91-BDD438A1AE5E
wdt:P433
3
wdt:P478
45
p:P356
wds:Q27851478-1568EA0D-D89C-4742-9B6C-2F068946384B
wdtn:P356
n7:BMT.2009.181
wdt:P356
10.1038/BMT.2009.181
skos:altLabel
Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma
p:P5875
wds:Q27851478-83AB7AA7-A445-4195-9F6F-8E0F47C2C27A
wdt:P5875
26711343
p:P10863
wds:Q27851478-7A5B0471-B03B-43D6-BDF4-DA751ECBED03
p:P6179
wds:Q27851478-E2972112-E9D7-4881-A339-3DFFBF8242B8
wdt:P10863
10.1038/bmt.2009.181
wdt:P6179
1034641898
p:P932
wds:Q27851478-DAC9A97F-AA85-4F8D-A806-D9F55407B134
wdt:P932
2836387